RCD regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
Overview
RCD regimen refers to a regimen consisting of rituximab, cyclophosphamide, and dexamethasone used to treat monoclonal Ig deposit-related glomerulopathy and indolent non-Hodgkin lymphomas.[1] and autoimmune cytopenias associated with chronic lymphocytic leukemia.[2]
Regimen
Regimen
RRituximab
CCyclophosphamide
DDexamethasone
References
References
- ↑ 1.0 1.1 Perry M, Delarche A, Ribes D, Vergez F, Guilbeau-Frugier C, Laurent C; et al. (2014). “Rituximab-cyclophosphamide-dexamethasone is highly effective in patients with monoclonal Ig deposit-related glomerulopathy and indolent non-Hodgkin lymphomas”. Am J Hematol. 89 (10): 969–73. doi:10.1002/ajh.23798. PMID 25043930.
- ↑ 2.0 2.1 Michallet AS, Rossignol J, Cazin B, Ysebaert L (2011). “Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia”. Leuk Lymphoma. 52 (7): 1401–3. doi:10.3109/10428194.2011.591005. PMID 21699387.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH